BACKGROUND: The transmission of hepatitis A virus (HAV) via blood transfusion has not been evidenced by molecular tracing so far. CASE REPORT: A 33-year-old asymptomatic female volunteer made a whole-blood donation. Thirteen days later an acute HAV infection was diagnosed. Retrospectively, a high viral load was measured by quantitative reverse transcription polymerase chain reaction (RT-PCR) in the quarantine fresh-frozen plasma (1.4 x 10(6) geq/mL), whereas immunoglobulin M (IgM) and G (IgG)/IgM anti-HAV were not detectable and the alanine aminotransferase levels not elevated. The red blood cells have just been transfused on Day 14. The 63-year-old male recipient already was HAV seropositive. He did not develop clinical symptoms of HAV and anti-HAV IgM was not detected. Seventy-five days later, a 25-fold increase in the anti-HAV IgG/IgM titer was observed. Demonstrable HAV ribonucleic acid (RNA) in the recipient by means of RT-PCR on Day 6, but not on Days 1 and 75, suggests that a transient reinfection did occur. Analyzed sequences of the HAV RNA in the donor and recipient were identical. CONCLUSION: For the first time, transfusion-transmitted HAV was evidenced by molecular and serologic tracing. The transmitted HAV can survive and replicate for a limited period despite the presence of anti-HAV IgG.
BACKGROUND: The transmission of hepatitis A virus (HAV) via blood transfusion has not been evidenced by molecular tracing so far. CASE REPORT: A 33-year-old asymptomatic female volunteer made a whole-blood donation. Thirteen days later an acute HAV infection was diagnosed. Retrospectively, a high viral load was measured by quantitative reverse transcription polymerase chain reaction (RT-PCR) in the quarantine fresh-frozen plasma (1.4 x 10(6) geq/mL), whereas immunoglobulin M (IgM) and G (IgG)/IgM anti-HAV were not detectable and the alanine aminotransferase levels not elevated. The red blood cells have just been transfused on Day 14. The 63-year-old male recipient already was HAV seropositive. He did not develop clinical symptoms of HAV and anti-HAV IgM was not detected. Seventy-five days later, a 25-fold increase in the anti-HAV IgG/IgM titer was observed. Demonstrable HAV ribonucleic acid (RNA) in the recipient by means of RT-PCR on Day 6, but not on Days 1 and 75, suggests that a transient reinfection did occur. Analyzed sequences of the HAV RNA in the donor and recipient were identical. CONCLUSION: For the first time, transfusion-transmitted HAV was evidenced by molecular and serologic tracing. The transmitted HAV can survive and replicate for a limited period despite the presence of anti-HAV IgG.
Authors: Suely Gonçalves Cordeiro da Silva; Luciane Almeida Amado Leon; Gilda Alves; Selma Magalhães Brito; Valcieny de Souza Sandes; Magda Maria Adorno Ferreira Lima; Marta Colares Nogueira; Rita de Cássia Barbosa da Silva Tavares; Jane Dobbin; Alexandre Apa; Vanessa Salete de Paula; Jaqueline Mendes de Oliveira Oliveira; Marcelo Alves Pinto; Orlando da Costa Ferreira; Iara de Jesus Ferreira Motta Journal: Transfus Med Hemother Date: 2015-11-24 Impact factor: 3.747
Authors: Florian Bihl; Damiano Castelli; Francesco Marincola; Roger Y Dodd; Christian Brander Journal: J Transl Med Date: 2007-06-06 Impact factor: 5.531
Authors: Evan M Bloch; Ruchika Goel; Silvano Wendel; Thierry Burnouf; Arwa Z Al-Riyami; Ai Leen Ang; Vincenzo DeAngelis; Larry J Dumont; Kevin Land; Cheuk-Kwong Lee; Adaeze Oreh; Gopal Patidar; Steven L Spitalnik; Marion Vermeulen; Salwa Hindawi; Karin Van den Berg; Pierre Tiberghien; Hans Vrielink; Pampee Young; Dana Devine; Cynthia So-Osman Journal: Vox Sang Date: 2020-07-20 Impact factor: 2.996